+279.0%
APH vs GSK
+66.9%
+212.1%
-28.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.9% | -0.6% | -0.3% | -1.0% |
| 7D | -5.0% | +5.2% | -10.2% | -4.6% |
| 30D | -8.4% | +10.2% | -18.5% | -7.7% |
| 3M | -4.5% | -0.9% | -3.6% | -4.1% |
| 6M | +25.3% | +3.5% | +21.8% | +25.7% |
| YTD | +18.9% | +7.2% | +11.7% | +19.6% |
| 1Y | +11.9% | +12.0% | -0.1% | +12.6% |
| All | +279.0% | +66.9% | +212.1% | +285.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling